Results 31 to 40 of about 10,605 (184)

Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial

Clinical and Translational Allergy, 2022
Background CT‐P39 is being developed as a biosimilar of reference omalizumab. This study aimed to assess the pharmacokinetic equivalence of CT‐P39 to European Union‐approved and United States‐licensed reference omalizumab (EU‐ and US‐omalizumab ...
Marcus Maurer, Sarbjit S. Saini, Kristi McLendon, Paul Wabnitz, Sunghyun Kim, Keumyoung Ahn, Suyoung Kim, Sewon Lee, Clive Grattan   +8 more
doaj   +1 more source

Biologics Adoption in CRSwNP and the Associated Decline in Endoscopic Sinus Surgery: A Longitudinal Claims Database Study

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Biologic treatments were introduced for chronic rhinosinusitis with nasal polyps (CRSwNP) in 2019. Treatment algorithms for medically refractory CRSwNP remain open, with patients choosing among surgery, biologics, or both. Real‐world utilization of surgery and biologics remains incompletely characterized.
Stephanie Shintani Smith, Sam L. Kaefer, Harsh Duvvuru, Robert C. Kern, Brent A. Senior, Vijay R. Ramakrishnan   +5 more
wiley   +1 more source

Efficacy and Predictors of Response to Biologic Therapy and Endoscopic Sinus Surgery in Patients With Nasal Polyps: A Systematic Review

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Biologics and endoscopic sinus surgery (ESS) treat refractory chronic rhinosinusitis with nasal polyposis (CRSwNP), but direct comparisons are lacking. We synthesized efficacy and subgroup data across randomized controlled trials (RCTs) of biologics and ESS.
Arun Chakravorty, Matthew E. Lin, Rory Lubner, Jess C. Mace, Jeffrey Suh, Jivianne Lee, Marilene Wang, Sarah Wise, Naweed Chowdhury, Zachary M. Soler, Justin Turner, Timothy L. Smith, Myung Sim, Daniel M. Beswick   +13 more
wiley   +1 more source

Omalizumab

Reactions Weekly
Kumar C, Patel P.
europepmc   +3 more sources

Appropriate selection for omalizumab treatment in patients with severe asthma?

European Clinical Respiratory Journal, 2017
Background: Omalizumab improves asthma control in patients with uncontrolled severe allergic asthma; however, appropriate patient selection is crucial. Information in this field is sparse.
Leo Nygaard, Daniel Pilsgaard Henriksen, Hanne Madsen, Jesper Rømhild Davidsen   +3 more
doaj   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl, Jonathan Grigg, Lubna Abuqayyas, Piotr Kuna, Gillian Hunter, Beata Pawlikowska, Jacob Leander, Michael Levin, Atul Gupta, James Paton, Katharine C. Pike, Jane R. Parnes, Gun Almqvist, Stephanie L. Roseti, on behalf of the study investigators   +14 more
wiley   +1 more source

Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma

ClinicoEconomics and Outcomes Research, 2019
Elizabeth A Brooks,1 Marc Massanari,2 Nicola A Hanania,3 Daniel J Weiner11TTi Health Research & Economics, Health Research & Economics, Westminster, MD, USA; 2Circassia Pharmaceuticals, Global Medical Affairs, Morrisville, NC, USA; 3Section of ...
Brooks EA, Massanari M, Hanania NA, Weiner DJ   +3 more
doaj  

Case Report: Omalizumab-associated hair loss: a case of eyebrow alopecia areata, literature review and FAERS database analysis

Frontiers in Medicine
Hair loss is a rare adverse reaction associated with omalizumab, with limited literature reports. The incidence, underlying mechanisms, and clinical characteristics of omalizumab-associated hair loss have not been clarified.
Qian Wang, Hua Lei, Ge Yang, Ying Li, Wei Liu, Lixia Zhang, Xiyuan Zhou   +6 more
doaj   +1 more source

Trends in the Asthma Burden Attributable to High Body Mass Index in Children Across 204 Countries and Territories, 1990–2021: An Analysis of the 2021 Global Burden of Disease Study

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT High body mass index (BMI) has been identified as a significant risk factor for childhood asthma. Given the rising prevalence of childhood obesity, assessing the impact of high BMI on asthma burden trends is imperative. Utilizing Global Burden of Disease (GBD) data, we estimated age‐, sex‐, geography‐, and sociodemographic index (SDI ...
Hua Li, Hai‐Yan Chen, Dong‐Zhi Zheng, Qiu‐Yi Liu, Jia‐Bing Li   +4 more
wiley   +1 more source

Efficacy of Endoscopic Sinus Surgery for Allergic Fungal Rhinosinusitis: A Systematic Review With Meta‐analysis

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective Endoscopic sinus surgery (ESS) plays a central role in the management of allergic fungal rhinosinusitis (AFRS); however, outcomes vary across studies. The goal of this study is to systematically review and synthesize evidence on the outcomes of ESS in patients with AFRS.
Amani Kais, Jad Kfouri, Ahmad R. Sedaghat, Charles Alex Riley, Chadi A. Makary   +4 more
wiley   +1 more source